Amyloid precursors and amyloidosis in rheumatoid arthritis

Bailliere's Best Practice and Research in Clinical Rheumatology

Volumn 13, Issue 4, 1999, Pages 615-628

  Cunnane, Gaye ^a   Whitehead, Alexander S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute phase response; Reactive amyloidosis; Serum amyloid A

Indexed keywords

ACUTE PHASE PROTEIN; CELL ADHESION MOLECULE; HIGH DENSITY LIPOPROTEIN; METALLOPROTEINASE; SERUM AMYLOID A;

AMYLOIDOSIS; CHEMOTAXIS; HUMAN; IMMUNOMODULATION; MACROPHAGE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0033385463     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.1999.0049     Document Type: Article

References (80)

1. Husby G. Amyloidosis. Seminars in Arthritis and Rheumatism. 22:1992;67-82.
2. Buxbaum J. The amyloidoses. Klippel J H, Dieppe P A. Rheumatology. 1998;8.27.1-8.27.10 Mosby, London.
3. Husby G. Nomenclature and classification of amyloid and amyloidoses. Journal of Internal Medicine. 232:1992;511-512.
4. Simms R W, Prout M N, Cohen A S. The epidemiology of AL and AA amyloidosis. Baillière's Clinical Rheumatology. 8:1994;627-634.
5. Hazenberg B P, van Rijswijk M H. Clinical and therapeutic aspects of AA amyloidosis. Baillière's Clinical Rheumatology. 8:1994;661-690.
6. Husebekk A, Skogen B, Husby G, Marhaug G. Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scandinavian Journal of Immunology. 21:1985;283-287.
7. Steel D M, Whitehead A S. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunology Today. 15:1994;81-88.
8. Malle E, De Beer F C. Human serum amyloid A (SAA) protein: a prominent acute phase reactant for clinical practice. European Journal of Clinical Investigation. 26:1996;427-435.
9. Kisilevsky R, Subrahmanyan L. Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function. Laboratory Investigation. 66:1992;778-785.
10. Betts J C, Edbrooke M R, Thakker R V, Woo P. The human acute phase serum amyloid A gene family: structure, evolution and expression in hepatoma cells. Scandinavian Journal of Immunology. 34:1991;471-482.
11. Urieli-Shoval S, Meek R L, Hanson R H. Human serum amyloid A genes are expressed in monocyte/macrophage cell lines. American Journal of Pathology. 145:1994;650-660.
12. Meek R L, Urieli-Shoval S, Benditt E P. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proceedings of the National Academy of Sciences of the United States of America. 91:1994;3186-3190.
13. Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y. Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. Journal of Histochemistry and Cytochemistry. 46:1998;1377-1384.
14. Uhlar, C, M, Whitehead, A, S, The kinetics and magnitude of the synergistic activation of the serum amyloid A promoter by IL-1β and IL-6 is determined by the order of cytokine addition, Scandinavian Journal of Immunology.
15. Rokita H, Loose L D, Bartle L M, Sipe J D. Synergism of interleukin 1 and interleukin 6 induces serum amyloid A production while depressing fibrinogen: a quantitative analysis. Journal of Rheumatology. 21:1994;400-405.
16. Jiang S L, Lozanski G, Samols D, Kushner I. Induction of human serum amyloid A in Hep 3B cells by IL-6 and IL-1 beta involves both transcriptional and post-transcriptional mechanisms. Journal of Immunology. 154:1995;825-831.
17. Betts J C, Cheshire J K, Akira S. The role of NF kappa B and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6. Journal of Biological Chemistry. 268:1993;25624-25631.
18. Gollaher C J, Bausserman L L. Hepatic catabolism of serum amyloid A during an acute phase response and chronic inflammation. Proceedings of the Society for Experimental Biology and Medicine. 194:1990;245-250.
19. Malle E, Steinmetz A, Raynes J G. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis. 102:1993;131-146.
20. Kushner I, Mackiewicz A. The acute phase response: an overview. Mackiewicz A, Kushner I, Baumann H. Acute Phase Proteins: Molecular Biology, Biochemistry and Clinical Applications. 1993;3-20 CRC Press, London.
21. Cunnane, G, Grehan, S, Geoghegan, S, Serum amyloid A in the assessment of early inflammatory arthritis, Journal of Rheumatology.
22. Hachulla E, Saile R, Parra H J. Serum amyloid A concentrations in giant cell arteritis and polymyalgia rheumatica: a useful test in the management of the disease. Clinical and Experimental Rheumatology. 9:1991;157-163.
23. Chambers R E, Hutton C W, Dieppe P A, Whicher J T. Comparative study of C reactive protein and serum amyloid A in experimental inflammation. Annals of the Rheumatic Diseases. 50:1991;677-679.
24. Maury C PJ. Comparative study of serum amyloid A and C reactive protein in disease. Clinical Science. 68:1985;233-238.
25. Marhaug G, Harklau L, Olsen B. Serum amyloid A protein in acute myocardial infarction. Acta Medica Scandinavica. 220:1986;303-306.
26. Cohen A S. Proteins of the systemic amyloidoses. Current Opinion in Rheumatology. 6:1994;55-67.
27. Hartmann A, Eide T C, Fauchald P. Serum amyloid A protein is a clinically useful indicator of acute renal allograft rejection. Nephrology, Dialysis, Transplantation. 12:1997;161-166.
28. Uguccioni M, Meliconi R, Lalli E. Serum amyloid A protein concentration in bone marrow transplantation for beta-thalassaemia. Journal of Clinical Pathology. 45:1992;348-351.
29. Mozes G, Friedman N, Shainkin-Kestenbaum R. Serum amyloid A: an extremely sensitive marker for intensity of tissue damage in trauma patients and indicator of acute response in various diseases. Journal of Trauma. 29:1989;71-74.
30. Weinstein P S, Skinner M, Sipe J D. Acute phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scandinavian Journal of Immunology. 19:1984;193-198.
31. Badolato R, Wang J M, Murphy W J. Serum amyloid A is a chemoattractant: induction of migration, adhesion and tissue infiltration of monocytes and polymorphonuclear leukocytes. Journal of Experimental Medicine. 180:1994;203-209.
32. +T cells. Journal of Immunology. 156:1996;1189-1195.
33. Zimlichman S, Danon A, Nathan I. Serum amyloid A, an acute phase protein, inhibits platelet activation. Journal of Laboratory and Clinical Medicine. 116:1990;180-186.
34. Patel H, Fellowes R, Coade S, Woo P. Human serum amyloid A has cytokine-like properties. Scandinavian Journal of Immunology. 48:1998;410-418.
35. Mitchell T I, Coon C I, Brinckerhoff C E. Serum amyloid A (SAA3) produced by rabbit synovial fibroblasts treated with phorbol esters or interleukin 1 induces synthesis of collagenase and is neutralized with specific antiserum. Journal of Clinical Investigation. 87:1991;1177-1185.
36. Migita K, Kawabe Y, Tominaga M. Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Laboratory Investigation. 78:1998;535-539.
37. De Beer F C, Mallya R K, Fagan E A. Serum amyloid A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet. 2:1982;231-234.
38. Yamamoto K I, Shiroo M, Migita S. Diverse gene expression for isotypes of murine serum amyloid A protein during acute phase reaction. Science. 232:1986;227-229.
39. Zahedi K, Gonnerman W A, De Beer F C. Major acute phase reactant synthesis during chronic inflammation in amyloid-susceptible and -resistant mouse strains. Inflammation. 15:1991;1-14.
40. Migita K, Eguchi K, Tsukada T. Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Laboratory Investigation. 75:1996;371-375.
41. Yamada T, Kluve-Beckerman B, Liepnieks J J, Benson M D. In vitro degradation of serum amyloid A by cathepsin D and other acid proteases: possible protection against amyloid fibril formation. Scandinavian Journal of Immunology. 41:1995;570-574.
42. Lavie G, Zucker-Franklin D, Franklin E C. Elastase-type proteases on the surface of human blood monocytes: possible role in amyloid formation. Journal of Immunology. 125:1980;175-180.
43. Fuks A, Zucker-Franklin D. Impaired Kupffer cell function precedes development of secondary amyloidosis. Journal of Experimental Medicine. 161:1985;1013-1028.
44. Ham D, Caouras V, Radzioch D, Gervais F. Degradation of amyloid A precursor protein SAA by macrophage cell lines obtained from amyloid resistant and susceptible strains of mice. Scandinavian Journal of Immunology. 45:1997;354-360.
45. Shirahama T, Miura K, Ju S T. Amyloid enhancing factor-loaded macrophages in amyloid fibril formation. Laboratory Investigation. 62:1990;61-68.
46. Kisilevsky R. From arthritis to Alzheimer's disease: current concepts on the pathogenesis of amyloidosis. Canadian Journal of Physiology and Pharmacology. 65:1987;1805-1815.
47. Niewold T A, Hol P R, van Andel A CJ. Enhancement of amyloid induction by amyloid fibril fragments in hamster. Laboratory Investigation. 56:1987;544-549.
48. Varga J, Flinn M S, Shirahama T. The induction of accelerated murine amyloid with human splenic extract. Probable role of amyloid enhancing factor. Virchows Archiv. 51:1986;177-185.
49. Friman C, Pettersson T. Amyloidosis. Current Opinion in Rheumatology. 8:1996;62-71.
50. Snow A D, Willmer J, Kisilevsky R. A close ultrastructural relationship between sulfated proteoglycans and AA amyloid fibrils. Laboratory Investigation. 57:1987;687-698.
51. Magnus J H, Stenstad T, Husby G. Proteoglycans, glycosaminoglycans and amyloid deposition. Baillière's Clinical Rheumatology. 8:1994;575-597.
52. Kisilevsky R, Young I D. Pathogenesis of amyloidosis. Baillière's Clinical Rheumatology. 8:1994;613-626.
53. Pepys M, Baltz M L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein. Advances in Immunology. 34:1983;141-212.
54. 123I-labeled serum amyloid P component. New England Journal of Medicine. 323:1990;508-513.
55. Li J J, McAdam K P. Human amyloid P component: an elastase inhibitor. Scandinavian Journal of Immunology. 20:1984;219-226.
56. Woo P, O'Brien J, Robson M, Ansell B M. A genetic marker for systemic amyloidosis in juvenile arthritis. Lancet. 2:1987;767-769.
57. Okuda Y, Takasugi K, Oyama T. Amyloidosis in rheumatoid arthritis: clinical study of 124 histologically proven cases. Ryumachi. 34:1994;939-946.
58. Helin H J, Korpela M M, Mustonen J T, Pasternack A I. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis and Rheumatism. 38:1995;242-247.
59. Bohle A, Wehrmann M, Eissele R. The long term prognosis of AA and AL renal amyloidosis and the pathogenesis of chronic renal failure in renal amyloidosis. Pathology, Research and Practice. 189:1993;316-331.
60. Ekelund L. Radiologic findings in renal amyloidosis. American Journal of Roentgenology. 129:1977;851-853.
61. Simons M, Isner J M. Assessment of relative sensitivities of noninvasive tests for cardiac amyloidosis in documented cardiac amyloidosis. American Journal of Cardiology. 69:1992;425-427.
62. Sumiya M, Ohya N, Shinoura H. Diffuse interstitial pulmonary amyloidosis in rheumatoid arthritis. Journal of Rheumatology. 23:1996;933-936.
63. Arakawa K, Kira J, Kobayashi T. Central nervous system involvement in amyloid A type amyloidosis. Journal of the Neurological Sciences. 142:1996;157-159.
64. Feldmann E, Tornabene J. Diagnosis and treatment of cerebral amyloid angiopathy. Clinics in Geriatric Medicine. 7:1991;617-630.
65. Lee J G, Wilson J AP, Gottfried M R. Gastrointestinal manifestations of amyloidosis. Southern Medical Journal. 87:1994;243-247.
66. Hawkins P N, Richardson S, MacSweeney J E. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. Quarterly Journal of Medicine. 86:1993;365-374.
67. Husby G. Amyloidosis and rheumatoid arthritis. Clinical and Experimental Rheumatology. 3:1985;173-180.
68. Berglund K, Keller C, Thysell H. Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatic disease. Annals of the Rheumatic Diseases. 46:1987;757-762.
69. David J, Vouyiouka O, Ansell B M. Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clinical and Experimental Rheumatology. 11:1993;85-90.
70. Zemer D, Pras M, Sohar E. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. New England Journal of Medicine. 314:1986;1001-1005.
71. Cathcart E S, Leslie C A, Meydani S N, Hayes K C. A fish oil diet retards experimental amyloidosis, modulates lymphocyte function and decreases macrophage arachidonate metabolism in mice. Journal of Immunology. 139:1987;1850-1854.
72. Hartmann A, Holdaas H, Fauchald P. Fifteen years' experience with renal transplantation in systemic amyloidosis. Transplant International. 5:1992;15-18.
73. Isobe T, Osserman E F. Effects of dimethyl sulfoxide (DMSO) on Bence-Jones proteins, amyloid fibrils and casein-induced amyloidosis. Wegelius O, Pasternack A. Amyloidosis. 1976;247-257 Academic Press, London.
74. Kisilevsky R, Lemieux L J, Fraser P E. Arresting amyloidosis in vivo using small molecule anionic sulphonates or sulphates: implications for Alzheimers disease. Nature Medicine. 1:1995;143-148.
75. Husby G. Treatment of amyloidosis and the rheumatologist. Scandinavian Journal of Rheumatology. 27:1998;161-165.
76. Tjernberg L O, Lilliehook C, Callaway D JE. Controlling amyloid beta-peptide fibril formation with protease-stable ligands. Journal of Biological Chemistry. 272:1997;12601-12605.
77. Botto M, Hawkins P N, Bickerstaff M CM. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nature Medicine. 3:1997;855-859.
78. Gaughan D J, Steel D M, Whitehead A S. Ribozyme mediated cleavage of acute phase serum amyloid A (A-SAA) mRNA in vitro. Febs Letters. 374:1995;241-245.
79. Stenstad T, Husby G. Brefeldin A inhibits experimentally induced AA amyloidosis. Journal of Rheumatology. 23:1996;93-100.
80. Brandwein S R, Sipe J D, Cohen A S. Combined treatment with terbutaline and aminophylline inhibits experimental amyloidosis in mice. Arthritis and Rheumatism. 37:1994;1757-1760.